Role of the N- and C-Terminal Domains in Binding of Apolipoprotein E Isoforms to Heparan Sulfate and Dermatan Sulfate: A Surface Plasmon Resonance Study
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index; 9 of the 59 sources its claims cite were checked for support.
Abstract
The ability of apolipoprotein E (apoE) to bind to cell-surface glycosaminoglycans (GAGs) is important for lipoprotein remnant catabolism. Using surface plasmon resonance, we previously showed that the binding of apoE to heparin is a two-step process; the initial binding involves fast electrostatic interaction, followed by a slower hydrophobic interaction. Here we examined the contributions of the N- and C-terminal domains to each step of the binding of apoE isoforms to heparan sulfate (HS) and dermatan sulfate (DS). ApoE3 bound to less sulfated HS and DS with a decreased favorable free energy of binding in the first step compared to heparin, indicating that the degree of sulfation has a major effect on the electrostatic interaction of GAGs with apoE. Mutation of a key Lys residue in the N-terminal heparin binding site of apoE significantly affected this electrostatic interaction. Progressive truncation of the C-terminal alpha-helical regions which favors the monomeric form of apoE3 greatly weakened the ability of apoE3 to bind to HS, with a much reduced favorable free energy of binding of the first step, suggesting that the C-terminal domain contributes to the GAG binding of apoE by the oligomerization effect. In agreement with this, dimerization of the apoE3 N-terminal fragment via disulfide linkage restored the electrostatic interaction of apoE with HS. Significantly, apoE4 exhibited much stronger binding to HS and DS than apoE2 or apoE3 in both lipid-free and lipidated states, perhaps resulting from enhanced electrostatic interaction through the N-terminal domain. This isoform difference in GAG binding of apoE may be physiologically significant such as in the retention of apoE-containing lipoproteins in the arterial wall.
Overview
CoChat Summary
TL;DR
Surface plasmon resonance shows that apoE binds heparan sulfate (HS) and dermatan sulfate (DS) via a two-step process, with the N-terminal domain dominating the initial electrostatic interaction and the C-terminal domain enhancing binding through oligomerization. ApoE4 binds HS and DS more strongly than apoE2 or apoE3 in both lipid-free and lipidated states.
Key findings
- Binding of apoE3 to HS and DS was two-step; compared with heparin, less sulfated HS and DS had slower first association and lower favorable free energy for the first step. Sulfation was 1.6, 0.7, and 0.7 sulfate groups per disaccharide for heparin, HS, and DS, respectively.
- The N-terminal heparin-binding-site mutation K146E greatly reduced HS/DS binding, whereas K233E behaved like wild-type. For HS binding, Rmax values were 1300, 180, and 1020 RU for apoE3 WT, K146E, and K233E, respectively.
- C-terminal truncation that favors monomeric apoE3 reduced HS binding and the favorable free energy of the first step, but Rmax values were not significantly different among full-length, 1–272, 1–260, and 1–250 apoE3 (880, 840, 1200, and 710 RU, respectively). Dimerization of the apoE3 22-kDa fragment restored kinetics comparable to full-length apoE3 (Kd: 0.18 ± 0.03 μM for apoE3, 6.2 ± 2.9 μM for 22-kDa monomer, and 0.61 ± 0.12 μM for 22-kDa dimer).
- ApoE4 showed two- to three-fold higher binding to HS and DS than apoE2 or apoE3 in lipid-free and lipidated states. Rmax values for lipid-free apoE2, apoE3, and apoE4 were 670, 810, and 1210 RU; for DMPC discs they were 360, 320, and 635 RU. The apoE4 E255A mutant still bound more than apoE3.
Methods
- SPR measurements used a Biacore X instrument with biotinylated GAG immobilized on a SA chip; apoE samples were flowed over the surface, and sensorgrams were globally fitted to a two-state binding model.
- Recombinant human apoE2, apoE3, apoE4, their 22-kDa fragments, K146E/K233E mutants, C-terminal truncation mutants (Δ251–299, Δ261–299, Δ273–299), a dimerized apoE3 22-kDa fragment, and DMPC discoidal complexes were prepared and analyzed.
- Far-UV circular dichroism and Trp fluorescence were used to assess conformation and urea-induced denaturation; statistical comparisons used t-tests with GraphPad Prism 5.0.
Limitations
- The paper states no formal limitations section.
- Evident from the text: several supporting analyses, including NaCl-dependence of binding, hydrophobic exposure upon dimerization, and some CD/urea data, are reported as “data not shown,” limiting independent assessment.
- Evident from the text: the study uses recombinant apoE and isolated biotinylated GAG on an SPR chip, which may not fully reproduce cell-surface proteoglycan presentation or the complex extracellular matrix environment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 Valid · 0 Not valid · 31 Not checked · 40 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“quantitative information on the interaction with various GAG molecules is limited (26, 34).”
What the sources say
- Partly supportedcites [26] Libeu C. P., 2001, J. Biol. Chem. sourceExperimental — accuracy not yet measured
Our copy nowhere states that quantitative information on apoE's interaction with various GAG molecules is limited; the passages that come closest address adjacent points. In the Results/Discussion section on measuring heparin-binding activities, the authors note that the heparin-binding activities of apoE K146E, apoE2 (R158C), apoE R142C and apoE R145C 'have been measured by different methods (21-23)' so that a direct comparison with one technique was needed — i.e. limited/comparable quantitative data for apoE variants, not for various GAGs. Another passage (Experimental Procedures/Discussion, citing Shuvaev et al.) says prior SPR measurements of the glycosaminoglycan binding affinity of apoE were done in phosphate buffer, which in their hands greatly reduces the affinities, questioning those quantitative values. Against the claim, the same paper itself reports quantitative-style GAG specificity data across several GAG molecules (heparin, bovine liver heparan sulfate, human aorta heparan sulfate, chondroitin sulfate, dermatan sulfate, N-desulfated heparin; RESULTS, Polysaccharide-binding Assay), so the 'limited' framing is the citing authors' generalization rather than something this source states for various GAGs. (LLM, conf=0.66)
- Supportedcites [34] Shuvaev V. V., 1999, FEBS Lett. source
The Introduction (p. 353) frames the work as the first characterization of apoE-GAG kinetics by SPR ('In the present work... we studied and characterized the kinetics of apoE-GAG interactions'), treating prior evidence as functional/qualitative rather than quantitative ('substantial evidence has been obtained for involving the heparin-binding activity of apoE in lipid metabolism...'). The Discussion reinforces this: earlier work had only shown that extensively sulfated GAGs bind apoE-containing emulsions with high affinity versus low-sulfated dermatan/chondroitin sulfate [27], and quantitative K D comparisons are drawn from other proteins (lipoprotein lipase, K D = 0.3 nM). No passage states the limitation in so many words, but our copy clearly treats quantitative apoE-GAG data as scarce, which supports this broad background statement. (LLM, conf=0.80)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast to the dominant role of the N-terminal site in apoE to GAG binding, the C-terminal site (basic residues around lysine 233) is not available for the interaction of full-length apoE with GAG (Fig. 4) (27, 28).”
What the sources say
- Not checked yetcites [27] Saito H., 2003, J. Biol. Chem. source
- Supportedcites [28] Futamura M., 2005, J. Biol. Chem. source
The introductory passage identifies the C-terminal heparin-binding site around lysine 233 and states that, in intact apoE, only the N-terminal site is available for interaction in both lipid-free and lipidated states. The lysine-mutation results also report that the K233E mutant binds heparin similarly to wild type. Page numbers were not supplied. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Since apoE4 has a lesser propensity to self-associate than apoE3 in solution (47) and the number of apoE molecules on DMPC discs is similar among apoE isoforms (52), it is unlikely that the higher ability of binding of apoE4 to GAG is due to the cooperative effects of the heparin binding sites.”
What the sources say
- Supportedcites [47] Sakamoto T., 2008, Biochemistry source
The citation (47) is attached to the premise that apoE4 has a lesser propensity to self-associate than apoE3 in solution, and our copy states exactly that: the Abstract concludes 'apoE4 self-associates less and binds less than apoE3 to HDL surfaces', the Results (Gel Filtration Chromatography) report that full-length apoE3 and apoE4 exist as monomeric and tetrameric forms 'with apoE4 being more monomeric', and the Discussion states 'ApoE3 favors a tetrameric form whereas apoE4 tends to be more monomeric'. The paper does qualify this (the effect was seen at its low 5 µg/ml concentration and is contrary to earlier reports credited to refs 17 and 43), but its own conclusion matches the claim. The heparin/GAG cooperativity conclusion is the citing authors' own inference; our copy contains no passage on glycosaminoglycan or heparin binding (searched: heparin, glycosaminoglycan, GAG), and the DMPC-disc stoichiometry point is attributed to a separate citation (52). (LLM, conf=0.86)
- Not checked yetcites [52] Schneeweis L. A., 2005, Biochemistry source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, such a hydrophobic exposure contributes to the second step of GAG binding (28)”
What the sources say
- Partly supportedcites [28] Futamura M., 2005, J. Biol. Chem. sourceExperimental — accuracy not yet measured
In “Two-step Mechanism of Binding of ApoE to Heparin,” the authors report that a mutant exposing a hydrophobic surface showed an increased contribution from the second binding step. They say this *implies* that hydrophobic interactions contribute to apoE–heparin binding at that step. The claim states the mechanism as fact and extends it from heparin to GAG binding generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The reduction of this free energy from the wild-type (1.5 and 1.3 kcal/mol for HS and DS, respectively) was much lower than that in heparin (2.7 kcal/mol) (Fig. 6 in ref 28).”
What the sources say
- Partly supportedcites [28] Futamura M., 2005, J. Biol. Chem. sourceExperimental — accuracy not yet measured
The section on lysine mutations (Fig. 6B; page unavailable) reports a decrease in favorable binding free energy relative to wild type for apoE mutants binding heparin. Our copy does not report the claimed 1.5 and 1.3 kcal/mol reductions for HS and DS, or give 2.7 kcal/mol as the heparin reduction; it therefore does not establish the numerical comparison. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
39 more claims
Create a free account to see all 79 claims and to verify the 50 references still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 14
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HSPG has been suggested to promote Aβ aggregation and neuronal uptake of extracellular tau; and ApoE-binding may be necessary for some of these effects15,16.”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“By contrast, APOE4 has increased binding affinity (up to two-fold) for heparin and HSPG over APOE3 (refs. 32–35).”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is important to note that HSPGs binding studies have shown that apoE4 had higher affinity than apoE3, apoE2 and apoE3 Christchurch, 29 and antibodies raised against the receptor‐binding region mimicked the protective effect of apoE2 and apoE3 Christchurch, 26”
From APOE and dementia – resequencing and genotyping in 105,597 individuals (2020) · cites this paper as [29]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ RESULTS
“apoE3 3.6 ± 0.6 2.5 ± 0.8 3.1 ± 1.0 4.2 ± 0.8 15 7.4 0.18 ± 0.03”
§ Abstract
“the overall equilibrium binding constant is calculated as KA = K1(1 + K2) and Kd = 1/KA.”
Citations
Cites
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Apolipoprotein E: Far More Than a Lipid Transport Protein
Mahley, R. W., & Rall, S. C. (2000) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.1.1.507 · Cited by 1,836
The Response-to-Retention Hypothesis of Early Atherogenesis
Williams, K. J., & Tabas, I. (1995) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.15.5.551 · Cited by 1,413
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830
Mahley, R. W., & Ji, Z.-S. (1999) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)33334-4 · Cited by 693
Three-Dimensional Structure of the LDL Receptor-Binding Domain of Human Apolipoprotein E
Wilson, C., Wardell, M. R., Weisgraber, K. H., Mahley, R. W., & Agard, D. A. (1991) · Science · doi:10.1126/science.2063194 · Cited by 678
Apolipoprotein E structure: insights into function
Hatters, D. M., Peters-Libeu, C. A., & Weisgraber, K. H. (2006) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2006.06.008 · Cited by 583 · cited 1×
“ApoE contains two independently folded functional domains; these are a 22-kDa N-terminal domain (residues 1–191) and a 10-kDa C-terminal domain (residues 216–299) linked by a hinge region (18,19).”
BackgroundKarlsson, R., & Fält, A. (1997) · Journal of Immunological Methods · doi:10.1016/s0022-1759(96)00195-0 · Cited by 568
Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors
Myszka, D. G. (1997) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(97)80157-7 · Cited by 552
Hepatic uptake of chylomicron remnants
Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
“ApoE also interacts with heparan sulfate proteoglycans (HSPG) [47] and binds heparin through two separate sites [48].”
BackgroundArboleda-Velasquez, J. F., Lopera, F., O’Hare, M., Delgado-Tirado, S., Marino, C., Chmielewska, N., Saez-Torres, K. L., Amarnani, D., Schultz, A. P., Sperling, R. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0611-3 · Cited by 598
Johnson, E. C. B., Carter, E. K., Dammer, E. B., Duong, D. M., Gerasimov, E. S., Liu, Y., Liu, J., Betarbet, R., Ping, L., Yin, L., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-00999-y · Cited by 561
“…interact with heparan sulfate proteoglycans, and loss of this binding interaction has been suggested as a possible mechanism for the remarkable protection afforded by the ApoE Christchurch loss-of-function mutation recently described in a presenilin-1 autosomal dominant AD mutation carrier 43,44 .”
Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis
Chen, Y., Strickland, M. R., Soranno, A., & Holtzman, D. M. (2021) · Neuron · doi:10.1016/j.neuron.2020.10.008 · Cited by 298
“On the other hand, a study applying fluorescence cross-correlation spectroscopy (FCCS) combined with alternating laser excitation (ALEX) characterized this interaction in solution, overcoming the immobilization restraint in SPR and noise signal from self-association in EPR assay (Ly et al., 2013).”
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
Cell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
“13,118) and are involved in the interneuronal spread of tau 119–121 .”
Grading the commercial optical biosensor literature—Class of 2008: ‘The Mighty Binders’
Rich, R. L., & Myszka, D. G. (2010) · Journal of Molecular Recognition · doi:10.1002/jmr.1004 · Cited by 167
Hepatitis C Virus Attachment Mediated by Apolipoprotein E Binding to Cell Surface Heparan Sulfate
Jiang, J., Cun, W., Wu, X., Shi, Q., Tang, H., & Luo, G. (2012) · Journal of Virology · doi:10.1128/jvi.07222-11 · Cited by 171
“ApoE is a glycosylated protein with at least two glycosylation sites and also forms different oligomers (20, 42, 80, 81, 84, 86).”
BackgroundHeparan sulfate proteoglycans present PCSK9 to the LDL receptor
Gustafsen, C., Olsen, D., Vilstrup, J., Lund, S., Reinhardt, A., Wellner, N., Larsen, T., Andersen, C. B. F., Weyer, K., Li, J.-P., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00568-7 · Cited by 116
Nelson, M. R., Liu, P., Agrawal, A., Yip, O., Blumenfeld, J., Traglia, M., Kim, M. J., Koutsodendris, N., Rao, A., Grone, B., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01480-8 · Cited by 120
“32–35).”
BackgroundInfluentialJendresen, C., Årskog, V., Daws, M. R., & Nilsson, L. N. G. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0835-4 · Cited by 94
Calandra, S., Tarugi, P., Speedy, H. E., Dean, A. F., Bertolini, S., & Shoulders, C. C. (2011) · Journal of Lipid Research · doi:10.1194/jlr.r017855 · Cited by 87
Snow, A. D., Cummings, J. A., & Lake, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710683 · Cited by 84
Molecular Mechanism of Apolipoprotein E Binding to Lipoprotein Particles
Nguyen, D., Dhanasekaran, P., Phillips, M. C., & Lund-Katz, S. (2009) · Biochemistry · doi:10.1021/bi9000694 · Cited by 64
“SPR has been employed successfully to assess the binding of apoE to proteoglycans (12-15) and members of the LDL receptor family (16) and to assess the binding of enzymes to lipoprotein particles (17, 18).”
Self-citationAPOE and dementia – resequencing and genotyping in 105,597 individuals
Rasmussen, K. L., Tybjærg‐Hansen, A., Nordestgaard, B. G., & Frikke‐Schmidt, R. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12165 · Cited by 64
Garai, K., Baban, B., & Frieden, C. (2011) · Biochemistry · doi:10.1021/bi1020106 · Cited by 57
Receptor-associated Protein Interacts with Amyloid-β Peptide and Promotes Its Cellular Uptake
Kanekiyo, T., & Bu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.015032 · Cited by 44
Marino, C., Perez‐Corredor, P., O'Hare, M., Heuer, A., Chmielewska, N., Gordon, H., Chandrahas, A. S., Gonzalez‐Buendia, L., Delgado‐Tirado, S., Doan, T. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13436 · Cited by 45
McMillan, I. O., Li, J., & Wang, L. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00247.2022 · Cited by 51
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 47
Lund‐Katz, S., Nguyen, D., Dhanasekaran, P., Kono, M., Nickel, M., Saito, H., & Phillips, M. C. (2009) · Journal of Lipid Research · doi:10.1194/jlr.m002055 · Cited by 39
Self-citationTakase, H., Tanaka, M., Yamamoto, A., et al. (2016) · Amyloid · doi:10.3109/13506129.2016.1168292 · Cited by 29
“37) consistent with our previous observation [19].”
Self-citationO'Callaghan, P. W., Noborn, F., Sehlin, D., Li, J., Lannfelt, L., Lindahl, U., & Zhang, X. (2014) · Amyloid · doi:10.3109/13506129.2013.879643 · Cited by 20
“Several members of the LDL receptor family are established ApoE receptors [20], and it seems likely that these may mediate ApoE uptake in the absence of LRP1 or cellular HS.”
BackgroundBeyond amyloid and tau: rethinking Alzheimer’s disease through less explored avenues
Gyimesi, M., Okolicsanyi, R. K., & Haupt, L. M. (2024) · Open Biology · doi:10.1098/rsob.240035 · Cited by 33
“Most recently, it was shown that ApoE4 also exhibits a threefold higher binding affinity for HSPGs than the neutral ApoE3 and protective ApoE2 isoforms [92].”
BackgroundApolipoprotein E Recognizes Alzheimer's Disease Associated 3‐O Sulfation of Heparan Sulfate
Mah, D., Zhu, Y., Su, G., Zhao, J., Canning, A., Gibson, J. M., Song, X., Stancanelli, E., Xu, Y., Zhang, F., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202212636 · Cited by 33
Apolipoprotein E2 and E3, but Not E4, Promote Retinal Pathologic Neovascularization
Masuda, T., Shimazawa, M., Hashimoto, Y., Kojima, A., Nakamura, S., Suemori, S., Mochizuki, K., Kawakami, H., Kawase, K., & Hara, H. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20539 · Cited by 27
Chen, G., Wang, M., Zhang, Z., Hong, D. K., Ahn, E. H., Liu, X., Kang, S. S., & Ye, K. (2025) · Neuron · doi:10.1016/j.neuron.2024.12.015 · Cited by 21
A manifesto for Alzheimer’s disease drug discovery in the era of disease-modifying therapies
Hering, H., Bussière, T., Liu, C., Glajch, K. E., Weihofen, A., Grogan, J. L., & Walsh, D. M. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00872-7 · Cited by 31
“Interestingly, of the three ApoE isoforms, ApoE4 has the highest affinity for heparin [190, 191], whereas the reduced binding of ApoE3-ch to HSPG and LDLR is akin to ApoE2 [79].”
Shibata, H., Yoshida, H., Izutsu, K., Haishima, Y., Kawanishi, T., Okuda, H., & Goda, Y. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.09.053 · Cited by 20
Zeng, X., Hou, Y., Luo, L., Ren, L., Wang, Y., Jin, X., Deng, L., Gao, Y., Zhang, D., Huang, J., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148054 · Cited by 34
Schultheis, N., Becker, R., Berhanu, G., Kapral, A., Roseman, M., Shah, S., Connell, A., & Selleck, S. B. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1012706 · Cited by 15
“More to the point of this discussion, the C-terminal segment of ApoE is important for heparan sulfate affinity, and ApoE dimerization appears to be critical for heparan sulfate binding (Yamauchi et al., 2008).”
BackgroundAssay of Biomarkers for Alzheimer’s Disease by Surface Plasmon Resonance
Yi, X., Chen, H., He, Y., & Wang, J. (2024) · Journal of Analysis and Testing · doi:10.1007/s41664-024-00299-x · Cited by 19
“Apolipoprotein E (apoE) is a 34 kDa plasma protein, serving as a crucial transporter of cholesterol in the central nervous system [64, 65].”
Guo, Q. J., Ping, L., Dammer, E. B., Duong, D. M., Yin, L., Xu, K., Shantaraman, A., Fox, E. J., Johnson, E. C. B., Roberts, B. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565824 · Cited by 11
Zhu, Z., Zhong, X., Wang, B., Lu, H., & Li, L. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00182 · Cited by 16
The Interplay of Apoes with Syndecans in Influencing Key Cellular Events of Amyloid Pathology
Hudák, A., Jósvay, K., Domonkos, I., Letoha, A., Szilák, L., & Letoha, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137070 · Cited by 16
Xia, M., Liu, Q., Zhang, W., Ge, J., & Mei, Z. (2025) · MedComm · doi:10.1002/mco2.70328 · Cited by 15
“Notably, a single residue changes between the APOE4 and APOE3 isoforms alters protein structure and function in two domains [141, 142], thereby directly or indirectly modifying the binding of APOE to various cell surface receptors [143, 144].”
Kawasaki, K., Ogiwara, N., Sugano, M., Okumura, N., & Yamauchi, K. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.12.018 · Cited by 9
Apolipoprotein E binds to and reduces serum levels of DNA-mimicking, pyrrolated proteins
Hirose, S., Hioki, Y., Miyashita, H., Hirade, N., Yoshitake, J., Shibata, T., Kikuchi, R., Matsushita, T., Chikazawa, M., Itakura, M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006629 · Cited by 10
“apoE binds with a high affinity to heparin and cell-surface heparan sulfate proteoglycan (25).”
BackgroundRecruitment of apolipoprotein E facilitates Herpes simplex virus 1 attachment and release
Liu, L., Bano, F., Conca, D. V., Thorsteinsson, K., Jayaweera, S. W., Avinens, D., Pace, H. P., Lövheim, H., Olofsson, A., & Bally, M. (2025) · npj Viruses · doi:10.1038/s44298-025-00099-9 · Cited by 9
Vascular Heparan Sulfate and Amyloid-β in Alzheimer’s Disease Patients
McMillan, I. O., Gearing, M., & Wang, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073964 · Cited by 7
“Previous studies have demonstrated that different ApoE isoforms have different binding affinities to HS, and ApoE4 has a threefold higher affinity for HS than ApoE2 and ApoE3 [56,57].”
BackgroundCurtis, D., & Initiative, A. D. N. (2021) · Journal of Neurogenetics · doi:10.1080/01677063.2020.1866569 · Cited by 5
“They also showed that APOE3ch has the lowest heparin binding ability of all APOE isoforms, whereas APOE4 had been shown to have a higher heparin affinity than APOE3 (Yamauchi et al., 2008).”
BackgroundInfluentialApolipoprotein E Recognizes Alzheimer's Disease Associated 3‐O Sulfation of Heparan Sulfate
Mah, D., Zhu, Y., Su, G., Zhao, J., Canning, A., Gibson, J. M., Song, X., Stancanelli, E., Xu, Y., Zhang, F., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202212636 · Cited by 3
Vascular Heparan Sulfate and Amyloid-β in Alzheimer’s Disease PatientsPreprint
McMillan, I. O., Gearing, M., & Wang, L. (2024) · Preprints.org · doi:10.20944/preprints202402.0567.v1 · Cited by 2
Recruitment of apolipoprotein E facilitates Herpes simplex virus 1 attachment, entry, and releasePreprint
Liu, L., Thorsteinsson, K., Bano, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.10.526562 · Cited by 2
Sambhariya, W. S., Rickman, C. B., D'Amore, P. A., Corradetti, G., Hageman, G. S., Howell, G. R., Marola, O. J., Phatnani, H. P., Philp, N. J., Sinha, D., et al. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101449 · Cited by 1
Mahley, R. W. (2025) · Springer eBooks · doi:10.1007/978-3-031-52641-1_2-1 · Cited by 2
Cerebrospinal Fluid Protein Profiles in Alzheimer’s Dementia Patients: A Bioinformatic Approach
Misra, A., Chakrabarti, S. S., Gambhir, I. S., Baghel, M. S., & Patil, Y. R. (2023) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_206_23 · Cited by 2
“[12] Multiple CSF proteomic studies have been performed on AD patients.”
BackgroundHeparan Sulfate in the Amyloidosis and Inflammation of Alzheimer’s Disease
O′Callaghan, P. W. (2011) · DiVA (Digitala Vetenskapliga Arkivet) · Cited by 1
APOB to Estimated APOB Ratio for Screening for the APOE2 Genotype
Auger, C., Sampson, M. L., Zubirán, R., Cole, J., Wolska, A. T., Otvos, J. D., Sniderman, A. D., & Remaley, A. T. (2026) · Clinical Chemistry · doi:10.1093/clinchem/hvag094
APOB to estimated APOB ratio for screening for the APOE2 genotypePreprint
Auger, C., Sampson, M. L., Zubirán, R., et al. (2026) · medRxiv · doi:10.64898/2026.01.29.26345063
“Compared to the more common APOE3 isoform, APOE2 has decreased affinity for proteoglycans (6), Low-Density Lipoprotein (LDL) Receptor and LDL Receptor Related Protein 1 (7) , which together mediate the removal of remnant lipoproteins from the circulation (8).”
Mahley, R. W. (2026) · Springer eBooks · doi:10.1007/978-3-031-96089-5_2
Gyimesi, M., Okolicsanyi, R. K., & Haupt, L. M. (2025) · Biochemical Society Transactions · doi:10.1042/bst20253088 · Cited by 2
“While the precise interactions in early AD development remain unclear, the high-risk ApoE4 isoform has been identified to have a threefold higher affinity for HS and association with cognitive decline [89,90].”
Factors Influencing Huntingtin Aggregation at Surfaces: Implications for Huntington’s Disease
Groover, S. E. (2020) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.7937
Alkuraya, F. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736847003.793566877
UT's Project Quest Reaches Deep into Instruction and Research
Danielson, W. A. (1988) · T.H.E. Journal Technological Horizons in Education
Metadata
- Authors
- Yamauchi, Y., Deguchi, N., Takagi, C., Tanaka, M., Dhanasekaran, P., Nakano, M., Handa, T., Phillips, M. C., Lund-Katz, S., & Saito, H.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan, Department of Biophysical Chemistry, Kobe Pharmaceutical University, Kobe 658-8558, Japan, and Lipid Research Group, The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4318
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-05-29
- Volume
- 47
- Issue
- 25
- Pages
- 6702-6710
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2844924
- OpenAlex
- W1987210223
- Cited by
- 53
- References
- 59
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 5 · 2023: 8 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 3 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 2 · 2012: 1
- FWCI
- 1.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL056083, HL-56083)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein E, apolipoprotein E isoforms, heparan sulfate, dermatan sulfate, glycosaminoglycan binding, N-terminal domain, C-terminal domain, electrostatic interactions, hydrophobic interactions, degree of sulfation, APOE3, APOE ε4, APOE2, oligomerization, disulfide bonds
- MeSH terms
- Animals, Apolipoproteins E, Binding Sites, Circular Dichroism, Dermatan Sulfate, Disulfides, Heparan Sulfate, Humans, Lysine, Mutation, Protein Binding, Swine, Surface Plasmon Resonance, Apolipoprotein E3, Apolipoprotein E4, Protein Multimerization, Static Electricity, Hydrophobic and Hydrophilic Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.